Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Mogg

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Journal of the American College of Cardiology|June 4, 2013
Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility studyAhmed Tawakol, Zahi A Fayad, Robin Mogg, et al.
Clinical Pharmacology and Therapeutics|January 4, 2025
Urinary Kidney Injury Biomarker Profiles in Healthy Individuals and After Nephrotoxic and Ischemic InjurySushrut S Waikar, Robin Mogg, Amanda F Baker, et al.
AIDS Research and Human Retroviruses|December 7, 2006
A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjectsTimothy W Tobery, Sheri A Dubey, Kiersten Anderson, et al.
The New England Journal of Medicine|May 7, 2025
BCG Revaccination for the Prevention of <i>Mycobacterium tuberculosis</i> InfectionAlexander C Schmidt, Lee Fairlie, Elizabeth Hellström, et al.
AIDS Research and Human Retroviruses|February 1, 2007
Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMCLisa S Kierstead, Sheri Dubey, Barbara Meyer, et al.
Vaccines|April 27, 2026
A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18-64 Years of Age (Preliminary Results)Rucha Dadhe, Juleen Gayed, Muneeb Iqbal, et al.
Lancet (London, England)|November 18, 2008
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialSusan P Buchbinder, Devan V Mehrotra, Ann Duerr, et al.
Journal for Immunotherapy of Cancer|February 26, 2022
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinomaRobert I Haddad, Tanguy Y Seiwert, Laura Q M Chow, et al.
Infectious Diseases and Therapy|July 1, 2025
Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 TrialOyeniyi Diya, Juleen Gayed, Francine S Lowry, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 22, 2007
Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assaySheri Dubey, James Clair, Tong-Ming Fu, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Journal of the American College of Cardiology|June 4, 2013
Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility studyAhmed Tawakol, Zahi A Fayad, Robin Mogg, et al.
Clinical Pharmacology and Therapeutics|January 4, 2025
Urinary Kidney Injury Biomarker Profiles in Healthy Individuals and After Nephrotoxic and Ischemic InjurySushrut S Waikar, Robin Mogg, Amanda F Baker, et al.
AIDS Research and Human Retroviruses|December 7, 2006
A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjectsTimothy W Tobery, Sheri A Dubey, Kiersten Anderson, et al.
The New England Journal of Medicine|May 7, 2025
BCG Revaccination for the Prevention of <i>Mycobacterium tuberculosis</i> InfectionAlexander C Schmidt, Lee Fairlie, Elizabeth Hellström, et al.
AIDS Research and Human Retroviruses|February 1, 2007
Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMCLisa S Kierstead, Sheri Dubey, Barbara Meyer, et al.
Vaccines|April 27, 2026
A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18-64 Years of Age (Preliminary Results)Rucha Dadhe, Juleen Gayed, Muneeb Iqbal, et al.
Lancet (London, England)|November 18, 2008
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialSusan P Buchbinder, Devan V Mehrotra, Ann Duerr, et al.
Journal for Immunotherapy of Cancer|February 26, 2022
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinomaRobert I Haddad, Tanguy Y Seiwert, Laura Q M Chow, et al.
Infectious Diseases and Therapy|July 1, 2025
Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 TrialOyeniyi Diya, Juleen Gayed, Francine S Lowry, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 22, 2007
Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assaySheri Dubey, James Clair, Tong-Ming Fu, et al.
Pageof 4